HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Yinci Zhang Selected Research

dactolisib

12/2021Retraction Note: The PI3K/mTOR Dual Inhibitor BEZ235 Nanoparticles Improve Radiosensitization of Hepatoma Cells Through Apoptosis and Regulation DNA Repair Pathway.
1/2021BEZ235 Increases the Sensitivity of Hepatocellular Carcinoma to Sorafenib by Inhibiting PI3K/AKT/mTOR and Inducing Autophagy.
3/2020The PI3K/mTOR dual inhibitor BEZ235 nanoparticles improve radiosensitization of hepatoma cells through apoptosis and regulation DNA repair pathway.
1/2020Resistance of hepatocellular carcinoma to sorafenib can be overcome with co-delivery of PI3K/mTOR inhibitor BEZ235 and sorafenib in nanoparticles.
1/2019BEZ235 increases sorafenib inhibition of hepatocellular carcinoma cells by suppressing the PI3K/AKT/mTOR pathway.
1/2019BEZ235 enhances chemosensitivity of paclitaxel in hepatocellular carcinoma through inhibiting the PI3K/Akt/mTOR pathway.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Yinci Zhang Research Topics

Disease

14Neoplasms (Cancer)
01/2022 - 11/2018
13Hepatocellular Carcinoma (Hepatoma)
12/2021 - 10/2018
4Liver Neoplasms (Liver Cancer)
07/2022 - 10/2018
2Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
09/2020 - 07/2020
1Neoplasm Metastasis (Metastasis)
01/2022
1Inflammation (Inflammations)
10/2021
1Hypoxia (Hypoxemia)
01/2021
1Fibrosarcoma
01/2021
1Breast Neoplasms (Breast Cancer)
12/2018

Drug/Important Bio-Agent (IBA)

7Sorafenib (BAY 43-9006)FDA Link
01/2021 - 10/2018
6dactolisibIBA
12/2021 - 01/2019
2gedatolisibIBA
01/2021 - 01/2019
2Oxaliplatin (Eloxatin)FDA LinkGeneric
01/2021 - 01/2019
2Phosphotransferases (Kinase)IBA
01/2021 - 01/2019
2GlypicansIBA
11/2020 - 03/2020
2Gefitinib (Iressa)FDA Link
09/2020 - 07/2020
2Cisplatin (Platino)FDA LinkGeneric
09/2020 - 07/2020
2Biological ProductsIBA
03/2020 - 12/2018
2Pharmaceutical PreparationsIBA
03/2020 - 11/2018
1AcidsIBA
07/2022
1Ion Channels (Ion Channel)IBA
07/2022
1Matrix Metalloproteinases (MMPs)IBA
07/2022
1Acid Sensing Ion ChannelsIBA
01/2022
1Trichloroethylene (Trichloroethene)IBA
10/2021
1CurcuminIBA
10/2021
1Therapeutic UsesIBA
01/2021
1LY3214996IBA
01/2021
1Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA
01/2021
1Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA
01/2021
1MK 2206IBA
01/2021
1Proteins (Proteins, Gene)FDA Link
01/2021
1AntigensIBA
11/2020
1Membrane Proteins (Integral Membrane Proteins)IBA
11/2020
1Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric
11/2020
1PolymersIBA
11/2020
1Cyclin D1IBA
11/2020
1thiazolyl blueIBA
09/2020
1Annexin A5IBA
09/2020
1Fluorescein (Funduscein)FDA LinkGeneric
09/2020
1ErbB Receptors (EGF Receptor)IBA
09/2020
1Tyrosine Kinase InhibitorsIBA
09/2020
1Propidium (Propidium Iodide)IBA
09/2020
1Paclitaxel (Taxol)FDA LinkGeneric
01/2019
1Trastuzumab (Herceptin)FDA Link
12/2018
1Maytansine (Maitansine)IBA
12/2018
1tocophersolanIBA
10/2018
1pluronic block copolymer P123IBA
10/2018

Therapy/Procedure

3Drug Therapy (Chemotherapy)
07/2022 - 01/2019
2Therapeutics
01/2022 - 10/2018
1Biological Therapy
12/2018